These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36782009)

  • 1. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
    Umemoto K; Sunakawa Y; Ueno M; Furukawa M; Mizuno N; Sudo K; Kawamoto Y; Kajiwara T; Ohtsubo K; Okano N; Matsuhashi N; Itoh S; Matsumoto T; Shimizu S; Otsuru T; Hasegawa H; Okuyama H; Ohama H; Moriwaki T; Ohta T; Odegaard JI; Nakamura Y; Bando H; Yoshino T; Ikeda M; Morizane C
    Br J Cancer; 2023 Apr; 128(8):1603-1608. PubMed ID: 36782009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.
    Huerta M; Martín-Arana J; Gimeno-Valiente F; Carbonell-Asins JA; García-Micó B; Martínez-Castedo B; Robledo-Yagüe F; Camblor DG; Fleitas T; García Bartolomé M; Alfaro-Cervelló C; Garcés-Albir M; Dorcaratto D; Muñoz-Forner E; Seguí V; Mora-Oliver I; Gambardella V; Roselló S; Sabater L; Roda D; Cervantes A; Tarazona N
    Transl Res; 2024 Sep; 271():105-115. PubMed ID: 38782356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.
    Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O
    Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage.
    Kirchweger P; Kupferthaler A; Burghofer J; Webersinke G; Jukic E; Schwendinger S; Weitzendorfer M; Petzer A; Függer R; Rumpold H; Wundsam H
    Eur J Surg Oncol; 2022 May; 48(5):1046-1053. PubMed ID: 34876329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
    Bando H; Nakamura Y; Taniguchi H; Shiozawa M; Yasui H; Esaki T; Kagawa Y; Denda T; Satoh T; Yamazaki K; Sunakawa Y; Kato T; Goto M; Yuki S; Nishina T; Oki E; Shinozaki E; Matsuhashi N; Takahashi N; Tsuji A; Ohtsubo K; Wakabayashi M; Ikeno T; Hata M; Odegaard JI; Yoshino T
    JCO Precis Oncol; 2022 Apr; 6():e2100535. PubMed ID: 35544728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
    Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA.
    Zvereva M; Roberti G; Durand G; Voegele C; Nguyen MD; Delhomme TM; Chopard P; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Brennan P; Foll M; Byrnes GB; McKay JD; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2020 May; 55():102462. PubMed ID: 32249202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
    Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
    Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.
    Labiano I; Huerta AE; Alsina M; Arasanz H; Castro N; Mendaza S; Lecumberri A; Gonzalez-Borja I; Guerrero-Setas D; Patiño-Garcia A; Alkorta-Aranburu G; Hernández-Garcia I; Arrazubi V; Mata E; Gomez D; Viudez A; Vera R
    Sci Rep; 2024 Jul; 14(1):16203. PubMed ID: 39003322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.